BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
BioLineRx Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$1.98−0.03 (-1.49%)
Close on Oct 19, 2026
- Market cap
- $5.28B
- P/E (TTM)
- –
- Dividend yield
- –
BioLineRx statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | BioLineRx | Industry median |
|---|---|---|
| Market Cap | $8.62M | $166.30M |
| Enterprise Value | $11.32M | $88.19M |
| PS Ratio | 7.30 | 3.65 |
| PB Ratio | 0.63 | 2.03 |
Enterprise value
| Measure | BioLineRx | Industry median |
|---|---|---|
| EV / Sales | 9.59 | 2.51 |
Income (trailing twelve months)
| Measure | BioLineRx | Industry median |
|---|---|---|
| Revenue | $1.18M | $58.34M |
| Gross Profit | $950.00K | $105.94M |
| Operating Income | -$10.29M | -$21.40M |
| EBITDA | -$9.76M | -$16.91M |
| EPS (Diluted) | $0.00 | -$0.83 |
Margins
| Measure | BioLineRx | Industry median |
|---|---|---|
| Gross Margin | 80.5% | 52.9% |
| Operating Margin | -871.8% | -44.0% |
| EBITDA Margin | -827.5% | -30.2% |
| FCF Margin | -686.4% | -9.27% |
Returns
| Measure | BioLineRx | Industry median |
|---|---|---|
| Return on Invested Capital (ROIC) | -59.7% | -32.4% |
| Return on Capital Employed (ROCE) | -52.0% | -38.1% |
Growth
| Measure | BioLineRx | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -95.9% | 5.96% |
Balance sheet
| Measure | BioLineRx | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.63M | $61.43M |
| Total Debt | $4.48M | $118.52M |
| Net Cash (Debt) | $148.00K | $15.35M |
| Net Cash Per Share | $0.00 | $0.66 |
| Equity (Book Value) | $13.77M | $49.09M |
| Book Value Per Share | $0.01 | $1.37 |
| Tangible Book Value | -$2.56M | $23.52M |
| Working Capital | $2.67M | $76.81M |
Financial position
| Measure | BioLineRx | Industry median |
|---|---|---|
| Current Ratio | 1.20 | 3.34 |
| Quick Ratio | 0.34 | 2.44 |
| Debt / Equity | 0.33 | 0.52 |
| Interest Coverage | -8.04 | -6.26 |
Cash flow (trailing twelve months)
| Measure | BioLineRx | Industry median |
|---|---|---|
| Operating Cash Flow | -$8.07M | -$12.35M |
| Capital Expenditures | -$25.00K | -$1.08M |
| Free Cash Flow | -$8.10M | -$20.22M |
| FCF Per Share | -$0.00 | -$0.42 |
Efficiency
| Measure | BioLineRx | Industry median |
|---|---|---|
| Asset Turnover | 0.03 | 0.39 |
| Inventory Turnover | 0.09 | 2.70 |
| Revenue Per Employee | $59.00K | $404.87K |
| Employee Count | 20 | 74 |
Dividends and yields
| Measure | BioLineRx | Industry median |
|---|---|---|
| FCF Yield | -94.0% | -8.72% |
| Buyback Yield | -161.3% | -0.59% |
| Shareholder Yield | -161.3% | 0.00% |
Shares
| Measure | BioLineRx | Industry median |
|---|---|---|
| Shares Outstanding | 2,610,810,000 | 58,127,000 |
| Shares Change (YoY) | 105.8% | 10.9% |
| Float | 2,600,670,000 | 49,136,700 |
| Shares Held by Insiders | 0.39% | 11.6% |
| Shares Held by Institutions | 0.00% | 59.4% |
Taxes
| Measure | BioLineRx | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | BioLineRx | Industry median |
|---|---|---|
| Altman Z-Score | -17.54 | -0.22 |
Calculated by StockData from BioLineRx's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.